HER-2 Expression in Secondary Circulating Prostate Cells does not Increase Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer
Journal: Austin Journal of Cancer and Clinical Research (Vol.1, No. 3)Publication Date: 2014-05-28
Authors : Murray NP; Reyes E; Fuentealba C; Orellana N; Dueñas R;
Page : 1-5
Keywords : Prostate cancer; Circulating prostate cells; HER-2; Biochemical failure;
Abstract
Introduction: There is evidence linking HER-2 expression in prostate cancer to disease progression and the development of androgen independent disease. HER-2 expression increases after androgen blockade and is associated with increased prostate cancer specific mortality. We present the effect of HER-2 expression in circulating prostate cells (CPCs) on the risk of biochemical failure and its association with standard clinic-pathological parameters. Methods and patients: Blood samples were taken 4 monthly after radical prostatectomy to detect CPCs using anti-PSA and standard immunocytochemistry. Samples positive for CPCs underwent analysis for HER-2 expression using the HercepTest® kit. Standard clinicopathological parameters were recorded. Kaplan Meier plots determined the different biochemical failure free survival curves. Results: 92 biochemical failure free men participated, 37/92(40.2%) of men had secondary CPCs detected. Biochemical failure was significantly more frequent in men CPC positive than those CPC negative (p=0.001). The expression of HER-2 in secondary CPCs did not increase biochemical failure free survival in comparison with men CPC (+) HER-2 (-). Conclusion: In men without biochemical failure the expression of HER-2 positive CPCs did not increase the risk of developing biochemical failure.
Other Latest Articles
- The Microenvironment as a Target for Therapy in Chronic Lymphocytic Leukemia
- Semi-Automated Co-Segmentation of Tumor Volume Using Multimodality Pet-Ct in Non-Small Cell Lung Cancer (NSCLC)
- Palifermin for Prevention of Oral Mucositis in Hematological Malignancies: Present Position and Future Perspectives
- Solid Tumors of the Pancreas: A Review
- Current Management and Molecular Targets of Synovial Sarcoma
Last modified: 2016-07-04 19:04:22